The majority of advanced breast cancer patients develop distal metastasis, including lung and bone metastasis. However, effective therapeutic strategies to prevent metastasis are still lacking. Decorin is a natural inhibitor of transforming growth factor β, which plays a pivotal role in tumor metastasis. An oncolytic adenovirus expressing decorin, rAd.DCN, has been developed previously. In an immune-competent breast tumor (4T1) model, intratumoral (i.t.) as well as intravenous (i.v.) delivery of rAd.DCN inhibited growth of orthotopic tumors and spontaneous lung metastasis. It was shown that i.t. delivery of rAd.DCN produced higher levels of transgene expression and evoked stronger oncolysis of the tumors compared to i.v. delivery. However, i.v. delivery resulted in higher amount of virus accumulation in the lungs and produced stronger responses to prevent tumor lung metastasis. Oncolytic adenovirus-mediated decorin expression in the tumors downregulated the decorin target genes and decreased epithelial mesenchymal transition markers. Decorin expression in lung tissues also increased Th1 cytokine expression, such as interleukin (IL)-2, IL-12, and tumor necrosis factor α, and decreased Th2 cytokines, such as transforming growth factor β and IL-6. Moreover, rAd.DCN treatment induced strong systemic inflammatory responses and upregulated CD8+ T lymphocytes. In conclusion, rAd.DCN inhibits tumor growth and lung metastasis of breast cancer via regulating wnt/β-catenin, vascular endothelial growth factor (VEGF), and Met pathways, and modulating the antitumor inflammatory and immune responses. Considering that i.v. delivery was much more effective in preventing lung metastasis, systemic delivery of rAd.DCN might be a promising strategy to treat breast cancer lung metastasis.
Get full access to this article
View all access options for this article.
References
1.
SiegelRL, MillerKD, JemalA. Cancer Statistics, 2017. CA Cancer J Clin, 2017; 67:7–30.
2.
FontanellaC, FanottoV, RihawiK, et al.Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clin Exp Metastasis, 2015; 32:819–833.
MinnAJ, GuptaGP, SiegelPM, et al.Genes that mediate breast cancer metastasis to lung. Nature, 2005; 436:518–524.
5.
LiuZ, YangY, ZhangX, et al.An oncolytic adenovirus encoding decorin and granulocyte macrophage colony stimulating factor inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic signals and via immune activation. Hum Gene Ther, 2017; 28:667–680.
6.
XuW, NeillT, YangY, et al.The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther, 2015; 22:247–256.
7.
XuW, ZhangZ, YangY, et al.Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases. Mol Ther, 2014; 22:1504–1517.
8.
HuZ, GuptaJ, ZhangZ, et al.Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther, 2012; 23:871–882.
9.
HuZ, RobbinsJS, PisterA, et al.A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy. Cancer Gene Ther, 2010; 17:235–243.
10.
ZhangZ, KrimmelJ, HuZ, et al.Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. Human Gene Ther, 2011; 22:1137–1142.
11.
SethP, WangZG, PisterA, et al.Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. Hum Gene Ther, 2006; 17:1152–1160.
12.
BorderWA, NobleNA, YamamotoT, et al.Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature, 1992; 360:361–364.
Sofeu FeugaingDD, GotteM, ViolaM. More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol, 2013; 92:1–11.
15.
GoyalA, NeillT, OwensRT, et al.Decorin activates AMPK, an energy sensor kinase, to induce autophagy in endothelial cells. Matrix Biol, 2014; 34:46–54.
16.
BuraschiS, NeillT, IozzoRV. Decorin is a devouring proteoglycan: remodeling of intracellular catabolism via autophagy and mitophagy. Matrix Biol, 2017Nov7 [Epub ahead of print]; DOI: 10.1016/j.matbio.2017.10.005.
17.
HuZB, WuCT, WangH, et al.A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Cancer Gene Ther, 2008; 15:173–182.
18.
RiesSJ, BrandtsCH, ChungAS, et al.Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med, 2000; 6:1128–1133.
19.
KaufmanHL, BinesSD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol, 2010; 6:941–949.
20.
GriggC, BlakeZ, GartrellR, et al.Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. Semin Oncol, 2016; 43:638–646.
21.
BrandesAA, CarpentierAF, KesariS, et al.A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol, 2016; 18:1146–1156.
22.
TamuraRE, HungerA, FernandesDC, et al.Induction of oxidants distinguishes susceptibility of prostate carcinoma cell lines to p53 gene transfer mediated by an improved adenoviral vector. Hum Gene Ther, 2017; 28:639–653.
23.
AgarwalP, GammonEA, SajibAM, et al.Cell-surface integrins and CAR are both essential for adenovirus type 5 transduction of canine cells of lymphocytic origin. PloS One, 2017; 12:e0169532.
24.
CajaF, VannucciL. TGFβ: a player on multiple fronts in the tumor microenvironment. J Immunotoxicol, 2015; 12:300–307.
25.
ZhuH, LuoH, ShenZ, et al.Transforming growth factor-β1 in carcinogenesis, progression, and therapy in cervical cancer. Tumour Biol, 2016; 37:7075–7083.
Tirado-RodriguezB, OrtegaE, Segura-MedinaP, et al.TGF- β: an important mediator of allergic disease and a molecule with dual activity in cancer development. J Immunol Res, 2014; 2014:318481.
28.
NymanJS, MerkelAR, UppugantiS, et al.Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease. Bone, 2016; 91:81–91.
29.
RodonJ, CarducciM, Sepulveda-SanchezJM, et al.Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in Phase 1 study in patients with advanced cancer. Invest New Drugs, 2015; 33:357–370.
30.
HuZ, GersenyH, ZhangZ, et al.Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer. Mol Ther, 2011; 19:1609–1618.
31.
EdwardsIJ. Proteoglycans in prostate cancer. Nat Rev Urol, 2012; 9:196–206.
32.
NashMA, DeaversMT, FreedmanRS. The expression of decorin in human ovarian tumors. Clin Cancer Res, 2002; 8:1754–1760.
33.
TroupS, NjueC, KliewerEV, et al.Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res, 2003; 9:207–214.
34.
BoströmP, SainioA, EigelieneN, et al.Human metaplastic breast carcinoma and decorin. Cancer Microenviron, 2017; 10:39–48.
35.
NeillT, PainterH, BuraschiS, et al.Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1α, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J Biol Chem, 2012; 287:5492–5506.
36.
FlavellRA, SanjabiS, WrzesinskiSH, et al.The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol, 2010; 10:554–567.
37.
MarcoeJP, LimJR, SchaubertKL, et al.TGF-beta is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat Immunol, 2012; 13:843–850.
38.
LiuS, ChenS, ZengJ. TGF-β signaling: a complex role in tumorigenesis (Review). Mol Med Rep, 2018; 17:699–704.
39.
TranTT, UhlM, MaJY, et al.Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol, 2007; 9:259–270.
40.
TanakaH, ShintoO, YashiroM, et al.Transforming growth factor beta signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep, 2010; 24:1637–1643.
41.
LiuVC, WongLY, JangT, et al.Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol, 2007; 178:2883–2892.
42.
BhomeR, Al SaihatiHA, GohRW, et al.Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside. New Horiz Transl Med, 2016; 3:9–21.
43.
LichtensteinDL, WoldWS. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther, 2004; 11:819–829.
44.
KoskiA, RajeckiM, GuseK, et al.Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. J Gene Med, 2009; 11:966–977.
45.
SmithTA, IdamakantiN, Marshall-NeffJ, et al.Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther, 2003; 14:1595–1604.
Rosewell ShawA, SuzukiM. Recent advances in oncolytic adenovirus therapies for cancer. Curr Opin Virol, 2016; 21:9–15.
48.
ShiS, ShiK, TanL, et al.The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxorubicin. Biomaterials, 2014; 35:4536–4547.
49.
GouM, MenK, ZhangJ, et al.Efficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimine. ACS Nano, 2010; 4:5573–5584.
50.
YangY, ZhaoH, JiaY, et al.A novel gene delivery composite system based on biodegradable folate-poly (ester amine) polymer and thermosensitive hydrogel for sustained gene release. Sci Rep, 2016; 6:21402.
51.
JiangD, ZhangX, YuD, et al.Tumor-microenvironment relaxivity-changeable Gd-loaded Poly(L-lysine)/carboxymethyl chitosan nanoparticles as cancer-recognizable magnetic resonance imaging contrast agents. J Biomed Nanotechnol, 2017; 13:243–254.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
